Effectiveness of the probiotic Bacillus subtilis DG101 to treat type 2 diabetes mellitus triggered by SARS‑CoV‑2 infection

The spore-forming probiotic Bacillus subtilis DG101 have proven to be an effective adjuvant intervention in the treatment of type 2 diabetes mellitus originally refractory to conventional therapy with metformin. Since the COVID-19 is able to trigger type 1 and type 2 diabetes mellitus which may not respond to medication and / or insulin levels, we were intrigued to unveil if B. subtilis DG101 probiotic intervention would be able to restored the physiological level of glucose and HbA1c among patients recovered from COVID-19. Herein, we report three cases of SARS-CoV-2-triggered type 2 diabetes mellitus resistant to insulin and metformin treatment in overweight patients which successfully responded to the incorporation of the probiotic B. subtilis DG101to the anti-diabetic therapy.